BioCentury
ARTICLE | Targets & Mechanisms

Triplet brings a new strategy to Huntington’s disease

Unveils preclinical POC data for its first DNA damage repair target

April 27, 2021 11:30 PM UTC

Preclinical data suggest that with a new target and route of administration, Triplet’s antisense oligonucleotide for Huntington’s disease may be effective where others have fallen short. 

The Cambridge, Mass.-based company unveiled preclinical data for its first target — DNA damage repair gene MSH3 — at the CHDI Foundation’s Annual HD Therapeutics conference on Tuesday, and provided the first preclinical proof of concept for its hypothesis that targeting DNA damage repair genes may help treat repeat expansion disorders. ...

BCIQ Company Profiles

Triplet Therapeutics Inc.